Popular Articles
Stretch Mark

National Review Of The Independent Reviewing Officer Service In Wales
The Care and Social Services Inspectorate Wales (CSSIW) published its report on the review of Independent Reviewing Officer (IRO) service in Wales.
generic viagra online
Polymorphism In Endostatin, An Angiogenesis Inhibitor, And Prostate Cancer Risk And Survival: A Prospective Study
UroToday.com - Angiogenesis is the process of new blood vessel formation in tumors, facilitating their growth. Endostatin is a cleavage product of collagen and is a potent inhibitor of endothelial cell proliferation and migration. Endostatin causes apoptosis in endothelial and tumor cells. Prostate cancer expresses angiogenic factors.
News of the day
Trubion Announces Acceptance Of Three Presentations On Its TRU-016 Product Candidate At The 2009 ASCO Annual Meeting
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced the acceptance of three data presentations on its proprietary product candidate, TRU-016, that will be given at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting May 29 through June 2 in Orlando, Fla. The presentations will include positive data from a Phase 1 clinical trial of TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), a preclinical study demonstrating the additive or synergistic effects of TRU-016 in combination with other therapeutic drugs for the treatment of non-Hodgkin"s lymphoma (NHL), and a preclinical study evaluating the effect of TRU-016 on direct apoptosis in CLL cells.
Diagnostics

LSUHSC Research On How Like Cell Receptor Systems Determine Very Different Functions, Supported By Grant

Andy Catling, PhD, Associate Professor in the Department of Pharmacology and the Stanley S. Scott Cancer Center at LSU Health Sciences Center New Orleans, has been awarded a $177, 500 supplement to his RO1 grant by the National Institute of General Medical Sciences to support his research on the mechanism by which seemingly similar cell receptor systems determine quite different functions influenced by hormones and drugs. "We are interested in how the generic ERK signaling pathway confers specific physiological outcomes such as proliferation, differentiation and cell migration," notes Dr. Catling. "We hypothesize that specificity is conferred by the action of input- and output-specific "scaffolding" molecules that assemble the pathway around growth factor receptors." The supplement was funded through the American Recovery and Reinvestment Act and will be used to help retain key personnel needed to identify and characterize ERK phosphorylation targets - proteins to which phosphate groups can be added, increasing or decreasing protein function - specified by the scaffold. These phosphorylation targets are involved in the development of disease. Dr. Ashok Pullikuth in Catling"s lab has recently identified a protein that functions in the intracellular movement and cell division activity of growth factor receptors as a novel phosphorylation target. Understanding this novel mechanism might be important in treating conditions that are dependent upon specific growth factor receptors, like some breast cancers in which the EGF receptor family drives growth and survival. "Our studies might provide insight into how specific functions of a pathway might be targeted therapeutically while not eliminating all essential housekeeping functions of the pathway," Dr. Catling says. "The beauty of research is that no one knows just how useful their findings will be in the future - there may be entirely unexpected benefits in addition to more predictable outcomes." These key personnel and the data they generate are essential to submit a competitive renewal of this RO1 grant in November. Leslie Capo Louisiana State University Health Sciences Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):